Bookmark and Share

BioActivity Data for Compound Pentostatin (CID 439693)

BioActivity Outcomes:
Active(14)
 
 
Inactive(74)
 
 
Inconclusive(2)
 
 
Unspecified(49)
 
 
Top Targets:
NR LBD AR(7)
 
 
NR LBD ER(7)
 
 
NR LBD GR(4)
 
 
NR LBD TR(3)
 
 
7tm 4(2)
 
 
BioAssay Types:
Literature(60)
 
 
 
 
Confirmatory(60)
 
 
 
Summary(15)
 
 
 
Screening(2)
 
 
BioAssay Categories:
In vitro(1)
 
 
In vivo(1)
 
 
Biochemical(12)
 
 
 
 
Toxicity(27)
 
 
 
 
ADME(22)
 
 
Cell-based(2)
 
 
BioActivity Types:
Potency(67)
 
 
 
Ki(8)
 
 
AC50(6)
 
 
IC50(2)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 139    Data Row: 139   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103589743]
Ki 1e-07Inhibition of adenosine deaminase [AID717435, Type: Literature]
View
2
[SID103589743]
Ki 1e-06Compound was tested for the inhibition of adenosine deaminase from calf intestine; Range of 0.01-0.001 nM [AID33670, Type: Literature]
View
3
[SID103589743]
Ki 1e-06Binding affinity towards calf spleen adenosine deaminase was determined [AID33661, Type: Literature]
View
4
[SID103589743]
Ki 2.5e-06The compound was tested in vitro for inhibition of human erythrocytic adenosine deaminase. [AID33969, Type: Literature]
View
5
[SID103589743]
Ki 2.5e-06Binding affinity (Ki) at calf intestinal adenosine deaminase. [AID33656, Type: Literature]
View
6
[SID103589743]
Ki 1e-05Binding affinity against Adenosine deaminase from calf intestinal mucosa was determined [AID33660, Type: Literature]
View
7
[SID103589743]
Ki 3.3e-05Inhibition constant against human adenosine deaminase was determined [AID33849, Type: Literature]
View
8
[SID103589743]
Ki 0.0001Compound was evaluated for the inhibition of adenosine deaminase [AID33846, Type: Literature]
View
9
[SID103589743]
IC50 0.25Compound was evaluated for the cytotoxicity against L1210 cells in presence of coformycin [AID98361, Type: Literature]
View
10
[SID103589743]
IC50 1.9Compound was evaluated for the cytotoxicity against L1210 cells in absence of coformycin [AID98360, Type: Literature]
View
11
[SID48416395]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
12
[SID144206967]
qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening]D(3) dopamine receptor isoform e [Homo sapiens] [gi:89191863]
View
13
[SID144206967]
qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening]D(3) dopamine receptor isoform e [Homo sapiens] [gi:89191863]
View
14
[SID103589743]
Adenosine deaminase inhibitor [AID742835, Type: other]Adenosine deaminase [gi:113339]
View
15
[SID103589743]
Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source] [AID1079933, Type: Literature]
View
16
[SID103589743]
Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] [AID1079948, Type: Literature]
View
17
[SID103589743]
Antitumor activity after administration (i.p.) in mice U937 cells at a dose of 0.025 mg/kg [AID116408, Type: Literature]
View
18
[SID103589743]
Antitumor activity (0.25 mg/kg, i.p.) on lymphoma U-937 tumor growth inoculated in mice [AID245705, Type: Literature]
View
19
[SID103589743]
Antitumor activity (2.5, i.p.) on lymphoma U-937 tumor growth inoculated in mice [AID245704, Type: Literature]
View
20
[SID103589743]
Antitumor activity after administration (p.o.) in mice U937 cells at a dose of 2.5 mg/kg [AID116411, Type: Literature]
View